TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19667022
Drug: Mitoxantrone induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone induction therapy followed by glatiramer acetate (GA)
Study: 22093991
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (2 × 15 mg for 1st postoperative 24 h; 2 × 10 mg for 2nd postoperative 24 h), paracetamol & tramadol hydrochloride tablets (8 × 1 tablet for postoperative 48 h) orally plus pethidine injection on demand (OXY group)
Study: 22093991
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia with 0.1% ropivacaine, 0.1 µg/ml sufentanil plus injected pethidine on demand (EDA group)
Study: 22093991
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (OXY group)
Study: 7793221
Drug: Propofol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.0 mg.kg‐1) followed by low dose (6 mg.kg‐1.h‐1) infusion
Study: 7793221
Drug: Propofol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.0 mg.kg‐1) followed by high dose (12 mg.kg‐1.h‐1) infusion
Study: 7793221
Drug: Methohexital (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (1.5 mg.kg‐1) followed by low dose (5 mg.kg‐1.h‐1) infusion
Study: 7793221
Drug: Methohexital (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (1.5 mg.kg‐1) followed by high dose (10 mg.kg‐1.h‐1) infusion
Study: 2286598
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once daily for seven days
Study: 2286598
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily for seven days
Study: 7291971
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous heparin (5000 units 8 hourly)
Study: 29274831
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1 g) preoperatively
Study: 18490495
Drug: Aliskiren 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 1200 mg
Study: 18490495
Drug: Aliskiren (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (both doses)
Study: 10485152
Drug: Insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetes patients
Study: 29898030
Drug: Topical Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Erythropoietin (EPO) - 1 mL of gel containing erythropoietin at a concentration of 4,000 IU mL‐1 applied to the donor site
Study: 29898030
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - 2 mL of gel alone applied to the donor site
Study: 29898030
Drug: Topical Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Erythropoietin (EPO)
Study: 20955402
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with Arginine Butyrate administered 5 d/week for 12 weeks
Study: 9652880
Drug: Captopril 75
Normalized name: captopril 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 75 mg/d and placebo (Group A)
Study: 9652880
Drug: Captopril 75
Normalized name: captopril 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 75 mg/d plus losartan 12.5 mg (first dose), then 25 mg/d (Group B)
Study: 8587088
Drug: Super Malic
Normalized name: Magnesium/Malic Acid/Niacin/Pyridoxine/Riboflavin 50 MG-200 MG-33.3 MG-16.67 MG-8.3 MG Oral Tablet [SUPER MALIC PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super Malic (200 mg malic acid and 50 mg magnesium, 3 tablets bid)
Study: 8587088
Drug: Super Malic
Normalized name: Magnesium/Malic Acid/Niacin/Pyridoxine/Riboflavin 50 MG-200 MG-33.3 MG-16.67 MG-8.3 MG Oral Tablet [SUPER MALIC PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super Malic (up to 6 tablets bid) during open label trial
Study: 2655501
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (1 mg)
Study: 2655501
Drug: Intrathecal methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal methadone (1 mg)
Study: 30536185
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium hyaluronate (SH) 0.18%
Study: 25604134
Drug: Erlotinib 25
Normalized name: erlotinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 25 mg
Study: 15359398
Drug: Preincisional wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional wound infiltration of 3 mg/kg ropivacaine (Group I)
Study: 15359398
Drug: Postincisional wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postincisional wound infiltration of 3 mg/kg ropivacaine (Group II)
Study: 9709393
Drug: Chronic metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic metoprolol treatment
Study: 7976801
Drug: dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimethindene maleate (new 'once a day formulation')
Study: 2596365
Drug: Gestoden triphasic
Normalized name: gestodene
DrugBank: Gestodene (DB06730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestoden triphasic formulation
Study: 2596365
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination pill containing desogrestrel
Study: 2596365
Drug: Gestoden triphasic
Normalized name: gestodene
DrugBank: Gestodene (DB06730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestoden triphasic formulation and Fixed dose combination pill containing desogrestrel
Study: 5440571
Drug: Oral lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lignocaine (500 mg taken with food)
Study: 5440571
Drug: Oral lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lignocaine (500 mg taken without food)
Study: 5440571
Drug: Oral lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lignocaine
Study: 26448381
Drug: Oral alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alfacalcidol therapy for 12 weeks
Study: 18819792
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m(2) intravenous (i.v.) on days 1 and 8 of each 21‐day cycle
Study: 14518352
Drug: Potassium and
Normalized name: Potassium and/or potassium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium and magnesium aspartate treatment for three weeks
Study: 10090430
Drug: Eptifibatide (Integrilin)
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide (Integrilin) administered to patients undergoing coronary angioplasty; monitored for anti-eptifibatide antibodies at baseline and 30 days after treatment.
Study: 10090430
Drug: Eptifibatide (Integrilin)
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide (Integrilin) administered to 28 healthy volunteers; 2 infusions 28 days apart, monitored at multiple time points (baseline, 28, 42, 56, 84, and 112 days).
Study: 7672152
Drug: Single IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IM injection of 100 mg progestogen (group 1)
Study: 7032947
Drug: Atenolol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50, 100, and 200 mg)
Study: 6585544
Drug: Topical steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroidal gel
Study: 6585544
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel and capsules (Control)
Study: 6585544
Drug: Sulindac (systemically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (systemically administered nonsteroidal anti-inflammatory drug)
Study: 30894009
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (dual-energy spectral imaging with reduced contrast dose at 0.3 gI/kg)
Study: 30894009
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (conventional 120kVp scanning protocol with contrast dose at 0.6 gI/kg)
Study: 24881806
Drug: Standard urotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard urotherapy treatment alone
Study: 24881806
Drug: Standard urotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard urotherapy + TENS (in children without previous treatment)
Study: 24881806
Drug: Standard urotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard urotherapy (in children without previous treatment)
Study: 23043295
Drug: Garlic oil
Normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic oil (0.005 mL/L) and ginger oil (0.005 mL/L) mixture
Study: 23043295
Drug: Garlic oil
Normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic oil (0.005 or 0.01 mL/L) and ginger oil (0.005 or 0.01 mL/L) mixture
Study: 23043295
Drug: Garlic oil
Normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic oil (0.02 mL/L)
Study: 23043295
Drug: Ginger oil
Normalized name: Ginger oil
DrugBank: Ginger oil (DB14690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger oil (0.01-0.02 mL/L)
Study: 10089089
Drug: Piperacillin 12
Normalized name: PIPERACILLIN 12/TAZOBACTAM 1.5GM/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 12 g/day plus tazobactam 1.5 g/day plus tobramycin 3 mg/kg per day
Study: 10089089
Drug: Ceftazidime 3
Normalized name: ceftazidime 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3 g/day plus tobramycin 3 mg/kg per day
Study: 31044463
Drug: Low-dose aripiprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aripiprazole (3 mg/day)
Study: 31044463
Drug: High-dose aripiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aripiprazole (up to 12 mg/day)
Study: 24096043
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) at low (1 μg/kg/hr) and high (3 μg/kg/hr) doses
Study: 24096043
Drug: Propofol (PROP)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (PROP) at low (100 μg/kg/m) and high (200 μg/kg/m) doses
Study: 21305525
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/m² (maximum 20 mg) once weekly for 12 months
Study: 15155194
Drug: Anidulafungin 50
Normalized name: anidulafungin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin 50 mg once daily
Study: 15155194
Drug: Anidulafungin 75
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin 75 mg once daily
Study: 15155194
Drug: Anidulafungin 100
Normalized name: anidulafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin 100 mg once daily
Study: 9988206
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen extract in a hydroglyceric solution
Study: 7751994
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms HB vaccine (Group A)
Study: 7751994
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms HB vaccine (Group B)
Study: 7751994
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms HB vaccine (Group C)
Study: 2077437
Drug: desglycinamide-(arg8) vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: desglycinamide-(arg8) vasopressin (DGAVP) 2 mg, nasal route
Study: 31498950
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg administered as three loading doses every 4 weeks, then every 8 weeks until week 48
Study: 25255447
Drug: LD-aminopterin (0.007,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-aminopterin (0.007, 0.014, 0.021 mg/kg once-weekly)
Study: 25255447
Drug: LD-aminopterin (0.007
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-aminopterin (0.007 mg/kg twice-weekly)
Study: 22696863
Drug: 0.1% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% timolol eye gel
Study: 17393018
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy (25 microg 17beta‐estradiol/125 microg norethisterone acetate applied every 3-4 days)
Study: 17393018
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (estradiol 1 mg and NETA 0.5 mg given once daily)
Study: 7519693
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg/o.d.)
Study: 30913304
Drug: mFOLFOX6 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 plus ziv-aflibercept (4 mg/kg every 2 weeks)
Study: 28163068
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) treatment on one side of the face
Study: 28163068
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment on the other side of the face
Study: 26759214
Drug: Alogliptin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (25 mg once daily)
Study: 24734338
Drug: Implant-link semi
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-link semi cement application
Study: 20861750
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) 2 g daily
Study: 18302285
Drug: Debio‐025 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio‐025 (1200 mg twice daily for 14 days)
Study: 17201845
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at sedative doses
Study: 14627865
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg transdermal 17beta‐estradiol (tE2, n = 33)
Study: 14627865
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral 17beta‐estradiol (oE2, n = 37)
Study: 14627865
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral 17beta‐estradiol combined with 25 microg gestodene (oE2 + G, n = 33)
Study: 10725476
Drug: Intravaginal indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal indomethacin (200 mg)
Study: 10725476
Drug: Intrarectal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal plus oral indomethacin (200 mg)
Study: 8504041
Drug: SPF 15+,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPF 15+, broad‐spectrum, water‐resistant sunscreen cream
Study: 8504041
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base without active ingredients (Control)
Study: 3551494
Drug: Guar diet
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar diet (5% of daily carbohydrate intake)
Study: 3551494
Drug: Guar +
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar + fructose diet (1 g of fructose/kg body weight, max 30 g/d)
Study: 21680251
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 127)
Study: 11083131
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg day(‐1))
Study: 8437068
Drug: Caudal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine 0.25%, 0.7 mL/kg
Study: 3743795
Drug: Follicle aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicle aspiration and CC use
Study: 3743795
Drug: No CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CC treatment
Study: 30025522
Drug: Magnesium (250
Normalized name: magnesium gluconate 12.5 mg magnesium (250 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (250 mg/day) plus Vitamin E (400 IU/day)
Study: 27660192
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus bevacizumab (16 cycles of 7.5 mg/kg bevacizumab by intravenous infusion over 90 min on day 1 of each cycle)
Study: 27660192
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (1250 mg/m2 twice daily for 14 days followed by a break for 7 days for 8 cycles)
Study: 24768895
Drug: MSG broth
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MSG broth (0.5 g/100 ml)
Study: 24768895
Drug: MSG+ broth
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MSG+ broth (0.05 g/100 ml)
Study: 24768895
Drug: Control preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preload (low-energy chicken flavor broth, 200 ml)
Study: 22475864
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg hemagglutinin antigen
Study: 22475864
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg hemagglutinin antigen
Study: 20417423
Drug: Fentanyl, 1
Normalized name: FentaNYL, 100 mcg buccal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl, 1 microg/kg, and ketamine, 0.5 mg/kg (group FK)
Study: 20417423
Drug: Fentanyl, 1
Normalized name: FentaNYL, 100 mcg buccal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl, 1 microg/kg, and normal saline solution (group F)
Study: 18600492
Drug: Zinc-monocysteine (ZMC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-monocysteine (ZMC) 25 mg twice daily
Study: 12022177
Drug: Tea polyphenols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea polyphenols (TP) 600 mg/d orally
Study: 1376694
Drug: Acetorphan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetorphan (200 mg)
Study: 30719817
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.1 mg kg-1 hr-1)
Study: 29420994
Drug: l-Theanine
Normalized name: L-Theanine
DrugBank: Theanine (DB12444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Theanine
Study: 29420994
Drug: l-Theanine-Caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Theanine-Caffeine combination
Study: 25331395
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration and bone graft therapy
Study: 20589924
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of caffeine
Study: 12635747
Drug: highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: highly purified follicle stimulating hormone (pFSH)
Study: 7579435
Drug: Streptokinase 1,500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion
Study: 7579435
Drug: Streptokinase 250,000
Normalized name: streptokinase 250,000 unit INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase 250,000 IU over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours
Study: 2010447
Drug: Diltiazem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (10 mg/L in crystalloid potassium cardioplegia)
Study: 6838742
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine anaesthesia
Study: 27060836
Drug: Subcutaneous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous peginterferon beta‐1a (125 μg s.c.)
Study: 27060836
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a (44 μg s.c. three times per week)
Study: 27060836
Drug: Subcutaneous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous peginterferon beta‐1a
Study: 22240389
Drug: Fast dissolving
Normalized name: Mucinex Sinus-Max Day/Night Fast Dissolving Gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast dissolving oral film containing 4 mg dexamethasone
Study: 22240389
Drug: Tablet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing 8 mg dexamethasone
Study: 16965776
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg and placebo
Study: 17483542
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg and Candesartan 16 mg
Study: 17483542
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg and placebo
Study: 17483542
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Ramipril 10 mg and Candesartan 16 mg)
Study: 17483542
Drug: Candesartan therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan therapy
Study: 16305585
Drug: BMS‐193884 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐193884 (200 mg, oral)
Study: 9794714
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (placebo-controlled randomized trial)